GenVec, Inc.
Records under this name other than the patents GenVec, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 22 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,388,429 | Method for Propagating Adenoviral Vectors Encoding Inhibitory Gene Products Term ended Term ended Nov 8, 2026 · Medium confidence | Term ended | Term ended Nov 8, 2026 | Medium confidence |
| US 10,640,776 | Method for Propagating Adenoviral Vectors Encoding Inhibitory Gene Products Term ended Term ended Nov 8, 2026 · Medium confidence | Term ended | Term ended Nov 8, 2026 | Medium confidence |
| US 10,022,432 | Malaria Antigens and Methods of Use Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 9,951,351 | Adenoviral vector encoding human atonal homolog-1 (HATH1) Lapsed on the fee record Ended Apr 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 24, 2026 | From the USPTO record |
| US 11,279,951 | Adenoviral vector encoding human atonal homolog-1 (HATH1) Lapsed on the fee record Ended Mar 22, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 22, 2026 | From the USPTO record |
| US 9,833,502 | Malaria Antigens and Methods of Use Lapsed on the fee record Ended Dec 5, 2025 · High confidence | Lapsed on the fee record | Ended Dec 5, 2025 | High confidence |
| US 8,323,663 | Adenoviral vector-based foot-and-mouth disease vaccine Formerly held Lapsed on the fee record Ended Dec 4, 2024 · From the USPTO record | Lapsed on the fee record | Ended Dec 4, 2024 | From the USPTO record |
| US 6,998,263 | Methods of preparing and using a viral vector library Term ended Term ended Oct 23, 2022 · From the USPTO record | Term ended | Term ended Oct 23, 2022 | From the USPTO record |
| US 8,765,146 | Adenoviral vector-based malaria vaccines Formerly held Lapsed on the fee record Ended Jul 1, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jul 1, 2022 | From the USPTO record |
| US 6,740,525 | Adenoviral capsid containing chimeric protein IX Term ended Term ended Aug 6, 2021 · From the USPTO record | Term ended | Term ended Aug 6, 2021 | From the USPTO record |